BTAI — BioXcel Therapeutics Share Price
0.000.00%
Last trade - 00:00- $91.95m
- $127.33m
- $1.38m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 66.63 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -369.94% | ||
| Return on Equity | -1766.94% | ||
| Operating Margin | -12447.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.38 | 1.38 | 2.65 | 10.12 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Directors
- Peter Mueller NEC (65)
- Vimal Mehta PRE (60)
- Richard Steinhart CFO (64)
- Frank Yocca SVP (65)
- Javier Rodriguez SVP (49)
- Vincent O'Neill SVP (52)
- Matthew Wiley SVP (49)
- Krishnan Nandabalan OTH (58)
- June Bray IND (67)
- Sandeep Laumas IND (53)
- Michal Votruba IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 29th, 2017
- Public Since
- March 8th, 2018
- No. of Shareholders
- 12
- No. of Employees
- 74
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 33,436,513
- Address
- 555 Long Wharf Dr, NEW HAVEN, 06511-6107
- Web
- https://www.bioxceltherapeutics.com/
- Phone
- +1 2036438060
- Contact
- Brennan Doyle
- Auditors
- Ernst & Young LLP
Upcoming Events for BTAI
BioXcel Therapeutics Inc Annual Shareholders Meeting
BioXcel Therapeutics Inc Annual Shareholders Meeting
Q2 2024 BioXcel Therapeutics Inc Earnings Release
Similar to BTAI
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the BioXcel Therapeutics share price?
As of Today at 19:04 UTC, shares in BioXcel Therapeutics are trading at $2.75. This share price information is delayed by 15 minutes.
How has the BioXcel Therapeutics share price performed this year?
Shares in BioXcel Therapeutics last closed at $2.75 and the price had moved by -87% over the past 365 days. In terms of relative price strength the BioXcel Therapeutics share price has underperformed the S&P500 Index by -89.18% over the past year.
What are the analyst and broker recommendations for BioXcel Therapeutics?
The overall consensus recommendation for BioXcel Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the BioXcel Therapeutics dividend yield?
BioXcel Therapeutics does not currently pay a dividend.
Does BioXcel Therapeutics pay a dividend?
BioXcel Therapeutics does not currently pay a dividend.
When does BioXcel Therapeutics next pay dividends?
BioXcel Therapeutics does not currently pay a dividend.
How do I buy BioXcel Therapeutics shares?
To buy shares in BioXcel Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioXcel Therapeutics?
As of the previous close price of $2.75, shares in BioXcel Therapeutics had a market capitalisation of $91.95m.
Where are BioXcel Therapeutics shares listed?
Here are the trading details for BioXcel Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BTAI
What kind of share is BioXcel Therapeutics?
Based on an overall assessment of its quality, value and momentum BioXcel Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioXcel Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in BioXcel Therapeutics is $10.50. That is 281.82% above the last closing price of $2.75.
Analysts covering BioXcel Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.76 for the next financial year.
What is the trend in the BioXcel Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioXcel Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -3.92%.
As of the last closing price of $2.75, shares in BioXcel Therapeutics were trading -32.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioXcel Therapeutics PE Ratio?
The BioXcel Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioXcel Therapeutics?
BioXcel Therapeutics' management team is headed by:
- Peter Mueller - NEC
- Vimal Mehta - PRE
- Richard Steinhart - CFO
- Frank Yocca - SVP
- Javier Rodriguez - SVP
- Vincent O'Neill - SVP
- Matthew Wiley - SVP
- Krishnan Nandabalan - OTH
- June Bray - IND
- Sandeep Laumas - IND
- Michal Votruba - IND